Summit Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$367K Sell
6,059
-50
-0.8% -$2.92K 0.05% 128
2025
Q4
$330K Buy
6,109
+15
+0.2% +$722 0.05% 134
2025
Q3
$275K Sell
6,094
-566
-8% -$26.4K 0.04% 142
2025
Q2
$308K Sell
6,660
-3,035
-31% -$149K 0.05% 135
2025
Q1
$591K Buy
9,695
+1,783
+23% +$104K 0.1% 91
2024
Q4
$448K Hold
7,912
0.08% 105
2024
Q3
$409K Sell
7,912
-31
-0.4% -$1.45K 0.08% 111
2024
Q2
$330K Hold
7,943
0.07% 118
2024
Q1
$431K Sell
7,943
-555
-7% -$28.3K 0.09% 99
2023
Q4
$436K Buy
8,498
+600
+8% +$31.5K 0.1% 92
2023
Q3
$458K Hold
7,898
0.12% 86
2023
Q2
$505K Sell
7,898
-153
-2% -$10.3K 0.13% 80
2023
Q1
$558K Buy
8,051
+1
+0% +$71 0.15% 75
2022
Q4
$579K Buy
8,050
+1
+0% +$75 0.17% 73
2022
Q3
$572K Buy
8,049
+76
+1% +$5.51K 0.18% 70
2022
Q2
$614K Buy
7,973
+75
+0.9% +$5.71K 0.19% 69
2022
Q1
$577K Buy
7,898
+800
+11% +$53.7K 0.17% 80
2021
Q4
$443K Sell
7,098
-682
-9% -$40K 0.13% 97
2021
Q3
$460K Sell
7,780
-545
-7% -$35.9K 0.14% 82
2021
Q2
$556K Sell
8,325
-160
-2% -$10.4K 0.17% 74
2021
Q1
$536K Sell
8,485
-80
-0.9% -$4.98K 0.18% 74
2020
Q4
$531K Buy
8,565
+845
+11% +$52K 0.19% 72
2020
Q3
$465K Buy
7,720
+1,439
+23% +$86.6K 0.19% 68
2020
Q2
$369K Sell
6,281
-71
-1% -$4.25K 0.17% 73
2020
Q1
$354K Buy
6,352
+255
+4% +$15.6K 0.19% 70
2019
Q4
$391K Hold
6,097
0.17% 70
2019
Q3
$309K Hold
6,097
0.14% 78
2019
Q2
$276K Sell
6,097
-330
-5% -$15.4K 0.13% 85
2019
Q1
$307K Sell
6,427
-230
-3% -$11.5K 0.15% 77
2018
Q4
$346K Sell
6,657
-175
-3% -$9.4K 0.2% 66
2018
Q3
$424K Hold
6,832
0.2% 64
2018
Q2
$378K Sell
6,832
-169
-2% -$9.13K 0.18% 66
2018
Q1
$443K Sell
7,001
-74
-1% -$4.76K 0.21% 61
2017
Q4
$434K Sell
7,075
-134
-2% -$8.38K 0.21% 65
2017
Q3
$459K Sell
7,209
-173
-2% -$10.1K 0.23% 61
2017
Q2
$411K Sell
7,382
-400
-5% -$21.8K 0.22% 66
2017
Q1
$423K Sell
7,782
-494
-6% -$27.1K 0.24% 60
2016
Q4
$484K Hold
8,276
0.3% 54
2016
Q3
$446K Buy
8,276
+20
+0.2% +$1.28K 0.27% 55
2016
Q2
$607K Sell
8,256
-280
-3% -$19.8K 0.39% 41
2016
Q1
$545K Hold
8,536
0.36% 44
2015
Q4
$587K Sell
8,536
-511
-6% -$33.8K 0.4% 41
2015
Q3
$536K Hold
9,047
0.38% 46
2015
Q2
$602K Sell
9,047
-6
-0.1% -$395 0.41% 43
2015
Q1
$584K Buy
9,053
+460
+5% +$28.8K 0.41% 41
2014
Q4
$507K Sell
8,593
-276
-3% -$15.6K 0.37% 45
2014
Q3
$454K Sell
8,869
-200
-2% -$9.99K 0.35% 47
2014
Q2
$440K Sell
9,069
-200
-2% -$9.86K 0.34% 44
2014
Q1
$482K Sell
9,269
-100
-1% -$5.32K 0.39% 41
2013
Q4
$498K Hold
9,369
0.39% 39
2013
Q3
$434K Sell
9,369
-325
-3% -$14.3K 0.38% 41
2013
Q2
$433K Buy
+9,694
New +$421K 0.42% 35

Other funds holding BMY

Summit Asset Management's BMY Position: Q1 2026 in Review

Summit Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 0.82% in Q1 2026, selling an estimated $2.92K and leaving 6,059 shares worth $367K. The position accounts for 0.05% of the portfolio, ranked #128.

Summit Asset Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $614K in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Summit Asset Management held 6,059 shares of Bristol-Myers Squibb worth $367K as of Q1 2026.
  • Summit Asset Management sold 50 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.92K.
  • Bristol-Myers Squibb made up 0.05% of Summit Asset Management's portfolio in Q1 2026, its #128 holding.
  • Summit Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Summit Asset Management's Bristol-Myers Squibb position peaked at $614K in Q2 2022.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Summit Asset Management's 13F filing for Q1 2026, filed 8 May 2026.